Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1682

Sort by

Sort Order Select

Journal Articles

Integrated omics approaches to predict T-LBL relapse risk

Guillaume P. Andrieu, Vahid Asnafi

Blood (2021) 137 (17): 2280–2282.

https://doi.org/10.1182/blood.2020009599

Published: 2021

Journal Articles

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

Sofie Gottschalk Højfeldt, Kathrine Grell, Jonas Abrahamsson, Bendik Lund, Kim Vettenranta, Ólafur G. Jónsson, Thomas L. Frandsen, Benjamin O. Wolthers, Hanne Vibeke Marquart, Goda Vaitkeviciene, Kristi Lepik, Mats Heyman, Kjeld Schmiegelow, Birgitte Klug Albertsen

Blood (2021) 137 (17): 2373–2382.

https://doi.org/10.1182/blood.2020006583

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

Blood (2020) 136 (10): 1161–1168.

https://doi.org/10.1182/blood.2020005064

Published: 2020

Includes: Supplemental data

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Blood (2020) 135 (17): 1438–1446.

https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

Jason Moran, Kenneth A. Bauer

Blood (2020) 135 (5): 344–350.

https://doi.org/10.1182/blood.2019000917

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Rhonda E. Ries, MA, Amanda R. Leonti, MS, Timothy Junius Triche, Jr., PhD, Robert B. Gerbing, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Jenny L. Smith, MSc, MD, Todd M Cooper, DO, Jason E. Farrar, MD, Aniruddha J. Deshpande, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 461.

https://doi.org/10.1182/blood-2019-125943

Published: 2019

Journal Articles

Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma

Rachael M Andrie, John M Burke, MD, Christopher R. Flowers, MD MS, Nathan H Fowler, MD, Jeff P. Sharman, MD, Timothy A Quill, PhD, Kevin L Obholz, PhD, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 414.

https://doi.org/10.1182/blood-2019-128988

Published: 2019

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Blood (2019) 134 (Supplement_1): 644.

https://doi.org/10.1182/blood-2019-129926

Published: 2019

Journal Articles

Reduced Risk of Relapse for Total Body Irradiation + Fludarabine Compared to Busulphan + Fludarabine As "Reduced-Toxicity" Conditioning for Patients with Acute Myeloid Leukemia Treated with Allohsct in First Complete Remission. a Study By the Acute Leukemia Working Party of the EBMT

Sebastian Giebel, MD PhD, Myriam Labopin, MD, Malgorzata Maria Sobczyk Kruszelnicka, MD, Matthias Stelljes, Jenny Byrne, MD PhD, Nathalie Fegueux, MD, Dietrich W. Beelen, Montserrat Rovira, Alexandros Spyridonidis, MD PhD, Didier Blaise, MD PhD, Martin Bornhäuser, MD, Ihsan Karadoğan, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 255.

https://doi.org/10.1182/blood-2019-129993

Published: 2019

Journal Articles

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Blood (2019) 134 (Supplement_1): 257.

https://doi.org/10.1182/blood-2019-124921

Published: 2019

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Nilanjan Ghosh, MD PhD, Sairah Ahmed, MD, Carlos Litovich, MPH, Kwang Woo Ahn, PhD, Manoj Khanal, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 319.

https://doi.org/10.1182/blood-2019-121849

Published: 2019

Journal Articles

Validation of the Ottawa Score in Cancer Patients with Venous Thromboembolism. the Predicare Cohort Study

Guy Meyer, Celine Chapelle, Philippe Girard, MD, Florian Scotté, MD PhD, Anne Lamblin, Silvy Laporte, MS, PhD

Blood (2019) 134 (Supplement_1): 167.

https://doi.org/10.1182/blood-2019-129087

Published: 2019

Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 258.

https://doi.org/10.1182/blood-2019-126172

Published: 2019

Journal Articles

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Luciano J. Costa, MD PhD, Simona Iacobelli, Marcelo C. Pasquini, MD, Riddhi Modi, PhD, Luisa Giaccone, Joan Bladé, MD PhD, Stefan Schonland, Andrea Evangelista, Jose A. Perez-Simon, MD PhD, Parameswaran Hari, MBBS, MD, Elizabeth E. Brown, PhD MPH, Sergio A Giralt, MD, Francesca Patriarca, Edward A. Stadtmauer, MD FACP, Laura Rosinol, MD PhD, Amrita Y. Krishnan, MD, Goesta Gahrton, MD PhD, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 259.

https://doi.org/10.1182/blood-2019-121367

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 358.

https://doi.org/10.1182/blood-2019-129230

Published: 2019

NARROW

Integrated omics approaches to predict T-LBL relapse risk

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

How I treat warm autoimmune hemolytic anemia

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Reduced Risk of Relapse for Total Body Irradiation + Fludarabine Compared to Busulphan + Fludarabine As "Reduced-Toxicity" Conditioning for Patients with Acute Myeloid Leukemia Treated with Allohsct in First Complete Remission. a Study By the Acute Leukemia Working Party of the EBMT

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Validation of the Ottawa Score in Cancer Patients with Venous Thromboembolism. the Predicare Cohort Study

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only